Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PET-CT–guided radiation dose de-escalation with sintilimab plus GP induction followed by concurrent chemoradiotherapy in stage II/III nasopharyngeal carcinoma
ChiCTR2500106622Phase 2Not yet recruiting
- Sponsor
- Taizhou Hospital of Zhejiang Province
- Start
- Jul 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sintilimab in nasopharyngeal carcinoma (NPC), sponsored by Taizhou Hospital of Zhejiang Province. Primary endpoint: Major pathological/metabolic response (major PMR) rate after treatment. Planned start Jul 2025; status: not yet recruiting.
02
Drugs
sintilimab
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on ChiCTR2500106622.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500106622.